U.S. Food and Drug Administration
Protecting and Promoting Your Health
CDER 21st Century Review (Cont.)
Meetings facilitate complete and fileable applications. All applicants are strongly encouraged to request a meeting with the appropriate FDA review division during the pre-submission activity phase. Meeting types may include:
- Pre-Investigational New Drug (IND)
- End-of-Phase 1 (EOP1)
- Pre-NDA/BLA meeting
- Electronic pre-submission meetings
Click NEXT to continue.